DRAD vs. NDRA, NUWE, HSDT, TIVC, BSGM, QTI, SNGX, XCUR, THAR, and LGVN
Should you be buying Digirad stock or one of its competitors? The main competitors of Digirad include ENDRA Life Sciences (NDRA), Nuwellis (NUWE), Helius Medical Technologies (HSDT), Tivic Health Systems (TIVC), BioSig Technologies (BSGM), QT Imaging (QTI), Soligenix (SNGX), Exicure (XCUR), Tharimmune (THAR), and Longeveron (LGVN). These companies are all part of the "medical" sector.
ENDRA Life Sciences (NASDAQ:NDRA) and Digirad (NASDAQ:DRAD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, community ranking, earnings, profitability, risk and institutional ownership.
ENDRA Life Sciences has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Digirad has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500.
ENDRA Life Sciences has a net margin of 0.00% compared to ENDRA Life Sciences' net margin of -5.32%. ENDRA Life Sciences' return on equity of -3.75% beat Digirad's return on equity.
Digirad has higher revenue and earnings than ENDRA Life Sciences. Digirad is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.
1.2% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 11.4% of Digirad shares are owned by institutional investors. 4.8% of ENDRA Life Sciences shares are owned by company insiders. Comparatively, 12.5% of Digirad shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Digirad received 83 more outperform votes than ENDRA Life Sciences when rated by MarketBeat users. Likewise, 70.35% of users gave Digirad an outperform vote while only 62.67% of users gave ENDRA Life Sciences an outperform vote.
In the previous week, ENDRA Life Sciences had 5 more articles in the media than Digirad. MarketBeat recorded 5 mentions for ENDRA Life Sciences and 0 mentions for Digirad. Digirad's average media sentiment score of 0.00 equaled ENDRA Life Sciences'average media sentiment score.
Summary
Digirad beats ENDRA Life Sciences on 9 of the 13 factors compared between the two stocks.
Get Digirad News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRAD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DRAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
